NYUHSL Faculty Bibliography

Searched for:

Department/Unit:Cell Biology

Total Results:

14243

Antimicrobial agents & chemotherapy. 2015:59(8):5007-9.DOI: 10.1128/AAC.00274-15

In Vitro Activity of Dalbavancin against Drug-Resistant Staphylococcus aureus Isolates from a Global Surveillance Program

McCurdy, Sandra P; Jones, Ronald N; Mendes, Rodrigo E; Puttagunta, Sailaja; Dunne, Michael W

In over a decade (2002 to 2012) of Staphylococcus aureus surveillance testing on 62,195 isolates, dalbavancin was demonstrated to be active against isolates that were either susceptible or nonsusceptible to daptomycin, linezolid, or tigecycline. Nearly all (99.8%) multidrug-resistant methicillin-resistant S. aureus isolates were inhibited by dalbavancin at

PMCID:4505194

PMID: 25987636

ISSN: 1098-6596

CID: 2216502

Annals of clinical microbiology & antimicrobials. 2015:14.DOI: 10.1186/s12941-015-0081-5

Use of vancomycin as a surrogate for dalbavancin in vitro susceptibility testing: results from the DISCOVER studies

Dunne, Michael W; Sahm, Dan; Puttagunta, Sailaja

BACKGROUND: Dalbavancin is a lipoglycopepetide antibiotic with activity against gram positive pathogens recently approved for treatment of acute bacterial skin and skin structure infections. Pending the introduction of antimicrobial susceptibility tests, we examined the utility of vancomycin inhibitory concentrations to predict dalbavancin susceptibility in a panel of isolates obtained from phase 3 registration studies. FINDINGS: 99.6% of Staphylococcus aureus and 99.0% of beta-hemolytic streptococci which are susceptible to vancomycin will have an MIC at or below the US FDA susceptibility breakpoint for dalbavancin. CONCLUSION: Vancomycin should be considered as a surrogate for in vitro dalbavancin susceptibility testing.

PMCID:4389583

PMID: 25885674

ISSN: 1476-0711

CID: 2216512